

1 **Viper toxins affect membrane characteristics of human erythrocytes**

2 Virginia Doltchinkova ^{1*}, Stoyl Stoylov ² and Plamena R. Angelova ³

3 ¹ Department of Biophysics and Radiobiology, Faculty of Biology, Sofia University “St.
4 Kliment Ohridski”, 1164 Sofia, Bulgaria

5 ² “Rostislav Kaischew” Institute of Physical Chemistry, Bulgarian Academy of Sciences,
6 1113 Sofia, Bulgaria

7 ³ Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of
8 Neurology, London WC1N 3BG, UK

9

10 * *Correspondence to:* vdoltchinkova@gmail.com

11

12 **Abstract:** Elucidating electrokinetic stability by which surface charges regulate toxins
13 interaction with erythrocytes is crucial for understanding the cell functionality.
14 Electrokinetic properties of human erythrocytes upon treatment of Vipoxin , phospholipase
15 A₂ (PLA₂) and Vipoxin acidic component (VAC), isolated from *Vipera ammodytes*
16 *meridionalis* venom were studied using particle microelectrophoresis. PLA₂ and Vipoxin
17 treatments alter the osmotic fragility of erythrocyte membranes. The increased stability of
18 cells upon viper toxins is presented by the increased zeta potential of erythrocytes before
19 sedimentation of cells during electric field applied preventing the aggregation of cells. Lipid
20 peroxidation of low dose toxin-treated erythrocytes shows reduced LP products compared to
21 untreated cells. The apparent proton efflux and conductivity assays are performed and the
22 effectiveness PLA₂>Vipoxin>VAC is discussed. The reported results open perspectives to a
23 further investigation of the electrokinetic properties of the membrane after viper toxins
24 treatment to shed light on the molecular mechanisms driving the mechanisms of
25 inflammation and neurodegenerative diseases.

26

27

28

29

30 **Keywords:** *erythrocytes, viper toxins, surface charge, lipid peroxidation,*
31 *microelectrophoresis, proton transport, conductivity*

32 1. Introduction

33 Antimicrobial peptides have a widespread application as a key component of the immune
34 defense systems. The activity of bee venom melittin is widely studied against
35 microorganisms causing disturbance of membrane structure as a result of deformation and
36 lipid extraction [1-3]. Viper toxins as another type of antimicrobial peptides and model of
37 toxins [4] are studied in order to clarify the biophysical characteristics of erythrocyte
38 membranes during and after treatment. Important as structural models of membrane
39 organization, erythrocytes carry negative surface electrical charge at physiological pH due to
40 carboxyl groups of sialic acids in the cell membrane. This charge varies in different disease
41 condition which can be determined by electrokinetic potential values [5]. The negative
42 charges on the cells prevent erythrocyte aggregation and participate in immunohematological
43 reactions [6]. Human erythrocytes of healthy adult subjects are characterized by 5 fractions
44 of phospholipids: sphingomyelin, phosphatidylcholine, phosphatidylserine,
45 phosphatidylinositol, phosphatidylethanolamine, and diacylglycerol. The erythrocyte
46 membranes contain the following composition of phospholipids' fatty acids: myristic (14:0),
47 palmitic (16:0), palmitoleic (16:1), stearic (18:0), oleic (18:1), linoleic (18:2), linolenic
48 (C18:3), arachidic (C20:0), gondoic (C20:1), eicosadienoic (C20:2) and behenic (C22:0)
49 acids [7]. The erythrocyte membrane is composed of lipid domains exhibiting differential
50 local mechanical properties which could depend on the specific lipid domain composition
51 and on their differential association to membrane and cytoskeletal proteins [8]. The
52 electrostatic charge of a cellular membrane has an important role in binding of multiple
53 toxins to the cells [9, 10]. In view of their applications in prototypes of therapeutic agents
54 [11-15], the physicochemical properties and interactions of toxic components with diverse
55 model lipid systems or cells are investigated [16-18]. On the other hand, no reports are
56 available regarding the surface properties of erythrocytes upon viper toxins treatment. Our
57 rationale here was to study the relationship between the surface electrical charge and
58 membrane characteristics of erythrocytes in the presence of viper toxins in order to elucidate
59 their membrane stability. Viper toxins alteration of the membrane electrostatics is a result of

60 the generation of Van der Waals repulsive forces between the erythrocytes, preventing the
61 aggregation of the cells. Changes in proton transport and conductivity characterize the
62 permeability properties of the erythrocytes. The significance of lipid peroxidation of viper
63 toxins-treated membranes reports for the reduced free radical products at low concentrations
64 of toxins.

65 Solute movements across the erythrocyte membranes involve mainly the extracellular proton
66 concentration (H^+_{ext}) in time, as well as the cotransport of Cl^- and H^+ and its antiport against
67 other anions (OH^-) by the highly effective cycle of Jacobs-Stewart. According to the ionic
68 states in erythrocytes, the existence of stable equilibrium (quazi - equilibrium "C" state)
69 characterizes the permeability balance of all the anions and protons, keeping the preliminary
70 content of Na^+ and K^+ [19]. The main role of Band 3 (AE1, SLC4A1) membrane protein in
71 erythrocytes as an electro-neutral chloride/bicarbonate exchanger in alteration on the net
72 surface charge is proposed. Band 3 is a dimeric glycoprotein and contains a 911 amino acid
73 consisting of a N-terminal cytosolic domain (cdAE1, residues 1-360) responsible for the
74 interaction with cytoskeleton and a C-terminal membrane domain (mdAE1, residues
75 361-911) responsible for its transport function [20]. Band 3 function may be regulated by
76 lipids [21]. Determination of osmotic fragility and hematocrit on viper toxin-treated
77 erythrocytes as a function of concentrations are essentially important for the functionality of
78 the membrane [22, 23]. The present paper is concerned with electrokinetic and membrane
79 transport studies of human erythrocytes in isotonic solution before sedimentation of
80 erythrocytes in the presence of viper toxins.

81 The neurotoxin Vipoxin (*PDB: 1jlt/1aok*) is isolated from the venom of *V. ammodytes sp.*
82 *meridionalis* - one of the most toxic snakes in Europe inhabiting only Balkan Peninsula.
83 Vipoxin is a non-covalent ionic complex of two protein subunits: a basic and strongly toxic
84 Ca^{2+} - dependent secreted phospholipase A₂ (GIIA-Asp49 sPLA₂), Vipoxin basic component
85 to which further will be referred shortly as PLA₂ and an acidic, enzymatically inactive and
86 nontoxic component, originally named Vipoxin acidic component (VAC) [24]. The vipoxin
87 phospholipase A₂ (phosphatide-*sn*-2-acylhydrolase, PLA₂, EC 3.1.1.4) is one of the most

88 toxic phospholipases. By catalysing the hydrolysis of sn-glycero-3-phospholipids at the sn-2
89 ester bond, they release 1-lyso-phosphatidylcholine and a free acid, e.g. arachidonic acid,
90 which takes part in the second messenger system cell signalling [25, 26]. Difference in the
91 ionization behaviour of the various phenolic hydroxyl groups in the toxic PLA₂ is reported:
92 (i) three phenolic hydroxyls are accessible to the solvent and titrate normally, with a pK_{eff} =
93 10.45; (ii) three residues are partially 'buried' and participate in hydrogen bonds with
94 neighbouring functional groups with a pK_{eff} = 12.17; (iii) two tyrosines with a pK_{eff} = 13.23
95 are deeply 'buried' in the hydrophobic interior of PLA₂ [27] According to Matsui and
96 co-workers [28] venom of *Protobothrops flavoviridis* PflLys 49-PLA₂ Basic Protein II
97 harbours seven intramolecular disulphide bonds, thus 12% of the total 122 amino acids (14
98 Cys residues) contributes to covalent bond formation. Such a large number of intramolecular
99 disulphide bonds may contribute to this unusual behaviour of this protein, i.e.
100 oligomerization by a protein denaturant.

101 Cytoskeletal rearrangements in human red blood cells induced by snake venoms have been
102 reported [29]. According to Vipoxin crystal structure investigations, the VAC and PLA₂ bind
103 within their hydrophobic sides by complementary, well-fitted hydrophobic interactions and
104 the complex is stabilized by electrostatic interactions between the positively charged PLA₂
105 and negatively charged VAC [30]. According to Devendjiev et al. [31] there is no evidence
106 for the complex 'recognition site' involving residues Phe³, Trp³¹ and Tyr¹¹⁹ of the molecules
107 of VAC. In the PLA₂-subunit the side chains of His⁴⁸, Asp⁹⁹ and Tyr⁵² form an active site which
108 is conserved in all phospholipases [32]. The positively charged alkylammonium side chain of
109 Lys⁶⁹ may satisfy the need for partial neutralisation in the region of the structurally shielded
110 Asp⁴⁹ carboxylate in *Crotalus atrox* [33]. The ionic interaction between Lys⁶⁹ (VAC) and
111 Asp⁴⁹ (PLA₂) in vipoxin complex is occurred. Vipoxin has a high affinity for biogenic amine
112 receptors [34]. According to these investigations, the VAC component and PLA₂ bind within
113 their hydrophobic sides by complementary, well-fitted hydrophobic interactions and the
114 complex is stabilized by electrostatic interactions between the positively charged PLA₂ and

115 negatively charged Acidic Component [30]. PLA₂ is a more hydrophobic substance
116 possessing 31 hydrophobic amino acids, but VAC is more hydrophilic agent with 24
117 hydrophobic amino acids. Furthermore, it is proposed that in the Vipoxin complex, VAC
118 component shields the access of substrate molecules to the active site of the enzyme thus
119 lowering the enzyme activity. Different roles are attributed to the VAC component but no
120 one is still proved as a result mainly from the diversity of pharmacological effects of the toxic
121 PLA₂ component.

122 Erythrocyte membranes exhibit a lipid-protein ratio of ~1 and negatively charged lipids and
123 proteins contribute to the total surface electrical charge of the cells. The lipid bilayer is the
124 basic structural element of membranes where a small amount of oxidized lipid is enough to
125 cause a drastic increase in phospholipid bilayer permeability [35]. Lipid peroxidation
126 produces a wide variety of oxidation products. Among the many different aldehydes which
127 can be formed as secondary products during lipid peroxidation, malondialdehyde (MDA) is
128 the most mutagenic product of lipid peroxidation [36]. MDA is used a convenient biomarker
129 for lipid peroxidation of omega-3 and omega-4 fatty acids because of its facile reaction with
130 thiobarbituric acid (TBA). However, the thiobarbituric acid reacting substances test
131 (TBARS) is applied for *in vitro* studies.

132 We demonstrate novel findings in the electrokinetic properties of viper toxins interaction
133 with the erythrocyte membrane. The biomacromolecules possess different effective
134 electrostatic charge of binding to the membrane. The surface properties of human
135 erythrocytes upon Vipoxin, PLA₂ or VAC are studied. We find that the electrokinetic
136 properties of the erythrocyte membrane upon viper toxin treatment, respectively, reflect
137 changes in their electrophoretic mobility (EPM) and the zeta potential of the cells as a marker
138 for stability of the erythrocytes. EPM changes are responsible for the dynamics of the surface
139 electrical charge and the extent of modification in membrane surface. Osmotic behaviour,
140 hematocrit and lipid peroxidation as convenient biophysical methods for cell functionality
141 status are used. The erythrocytes are highly susceptible to oxidative stress [37]. The

142 relationship between the enhancement of net surface charge and proton efflux and
143 conductivity by viper toxins treatment is discussed. In order to determine the changes in free
144 radical products and the mechanism of the protective effect of low doses of viper toxins in
145 erythrocyte membranes is used. Viper toxins alter the shape of erythrocytes, proton transport
146 and electrical conductivity due to the generation of lipid peroxides [38].

147

148 **2. Materials and Methods**

149 *2.1. Materials*

150 All chemicals used in the present study are of analytical grade. Neuraminidase (*Vibrio*
151 *cholerae*, 5 U/mg enzyme); HEPES, N-(2-Hydroxyethyl) piperazine-N'- (2-ethanesulfonic
152 acid); Na₂HPO₄, Sodium phosphate dibasic; KH₂PO₄, Potassium phosphate monobasic are
153 purchased from Sigma-Aldrich (StLouis, MO) and the chemicals, as follows: CaCl₂, NaCl,
154 KCl; trichloroacetic acid; 2-thiobarbituric acid (TBA); NaN₃, sodium azide; Sucrose.
155 Bidistilled water from a quartz distiller for the preparation of all aqueous solutions is used.

156

157 *2.2. Isolation and purification of the Vipoxin and its components*

158 Isolation and purification of the Vipoxin and its components from the venom of the *Vipera*
159 *ammodytes meridionalis* is described previously [39]. The two components of the Vipoxin
160 (His-48 PLA₂ and Gln-48 PLA₂) after dissociation of the complex and purified are separated
161 [40]. Vipoxin is isolated from a crude venom of Bulgarian nose-horned viper *Vipera*
162 *ammodytes meridionalis* (Thracian Herpetological Society and National Centre of Infectious
163 and Parasitic Diseases, Bulgaria) using ion-exchange chromatography on SP-Sephadex C-50
164 (Pharmacia, Sweden) according to the procedure described previously [41]. Data related to
165 the purity of Vipoxin is presented in the supporting information (S1, Supporting Figure 1).

166 We have used the following viper toxin stock solutions: sPLA₂ (Mr 13800 Da, pI 10.4; 1.8
167 mg/mL) subunit, VAC (Mr 13740 Da, pI 4.6; 1.25 mg/mL) subunit and Vipoxin (Mr 27540
168 Da (5.3 mg/mL) and have done appropriate dilution of the toxins to 1:10 to 1:100 in the
169 relevant buffer.

170

171 *2.3. Erythrocytes preparation*

172 Erythrocytes were prepared from citrate - containing blood from the blood bank of phenotype
173 A Rh⁺ supplied by National Centre of Hematology and Perfusion in Sofia. Erythrocytes are
174 isolated after triplicate centrifugation with isotonic Hepes buffered saline and suspended in
175 the same buffer for microelectrophoresis measurements, Δ pH and conductivity analysis.
176 Erythrocytes were centrifuged (plasma and buffy coat removed) at 2000 x g for 5 min in a
177 microcentrifuge MIKRO 22R, *Hettich* (Germany), washed twice with isotonic Hepes
178 buffered saline: (25 mM Hepes, pH 7.5 (KOH), 130 mM NaCl, 3.7 mM KCl, 0.25 mM
179 CaCl₂). We used the phosphate - buffered saline (PBS), containing 137 mM NaCl, 10.1 mM
180 Na₂HPO₄, 1.8 mM KH₂PO₄ for determination of hematocrit, osmotic fragility and lipid
181 peroxidation measurements, respectively, where the stock suspension of erythrocytes were
182 then diluted to 1% hematocrit.

183

184 *2.4. Hematocrit and osmotic fragility tests*

185 We determine the hematocrit (Hct) by microcentrifugation (NF 048 NÜVE SANAYI
186 MALZEMELERI IMALAT VE TICARET A.S bench-top centrifuge). Hematocrit
187 adjustment was performed by blood centrifugation (12500 x g for 2 minutes), plasma
188 removal and addition of cells in the desired ratio to obtain 20% (v/v). The samples aliquoted
189 into Eppendorf tubes and homogenized.

190 We used the osmotic fragility (OF) test at different concentrations of PLA₂, VAC or Vipoxin
191 to determine the degree of hemolysis. The erythrocytes osmotic fragility is fixed [42] by
192 adding erythrocytes to series of hypotonic solutions with decreasing NaCl concentration (0.9
193 % – 0.3 % NaCl, i.e., 0.154 M – 0.05 M NaCl) at 5% Hct, incubation for 30 min at 25 °C with
194 gentle mixing. Afterwards, 1.5 mL samples of the erythrocytes suspensions incubates with
195 toxin components at 25 °C for 30 min. The erythrocytes incubated with different hypotonic
196 solutions are then centrifuged (12000 x g for 1 min) after that the supernatants are removed.
197 The hemoglobin of each supernatant was measured using absorbance at $\lambda=544$ nm and $\lambda=570$
198 nm immediately after centrifugation [43] by means of a spectrophotometer Epsilon (Thermo

199 Fischer Scientific Inc., MA, USA). The OF₅₀ (the concentration of NaCl that can induce
200 hemolysis of erythrocyte cells by 50%) is calculated by plotting the relationship between
201 absorbance at 544 nm or 570 nm, respectively, versus the concentration of NaCl solution.

$$202 \quad H\% = \frac{\text{Abs } (\lambda)\text{in NaCl}}{\text{Abs } (\lambda)\text{in Viper toxins}} \times 100 \quad (1)$$

203 Where Abs ($\lambda=544; \lambda=570$) in NaCl and Abs ($\lambda=544; \lambda=570$) in the presence of fixed concentrations of
204 50 nM (PLA₂, VAC or Vipoxin) are the absorbance of the release of hemoglobin into NaCl
205 solution and Viper toxins containing media, respectively.

206

207 *2.5. Treatment of erythrocytes with neuraminidase*

208 For neuraminidase (EC.3.2.1.18) treatment, 0.5 mL of erythrocytes were suspended in 1 mL
209 of HEPES buffered saline in the presence of 0.1 mL (10-50 mM IE) of diluted neuraminidase.

210 The concentrations of neuraminidase of 25 nM, 50 nM, 80 nM and 100 nM PLA₂ were added
211 and the suspension incubated for 60 min at 37 °C with constant gentle swirling. Control or
212 'Untreated' cells are suspended and incubated in a similar manner except no neuraminidase
213 was added. There was a sample containing fixed dose of 25 nM PLA₂ without neuraminidase
214 in the suspending medium.

215 Cells were washed with 1 mL of cold isotonic HEPES-buffered saline, pH 7.5 as above
216 described immediately after completion of the incubation. Aliquots were taken for
217 measurement of electrophoretic mobility. Samples (Ht 20%) were stored in refrigerator (4
218 °C) until use up to 4 h after erythrocyte preparation.

219

220 *2.6. Microelectrophoretic measurements*

221 Microelectrophoretic studies were performed in an OPTON Cytopherometer (Feintechnik
222 Ges, mb. H, Germany), using a rectangular glass cell and platinum electrodes. The
223 erythrocytes were diluted to 25 mL with HEPES buffered saline at 25 °C. The cells were
224 observed under a light microscope connected to a video camera (Video Camera head CH

225 1400 CE, Sony corporation, Japan) providing 800 x magnification, which allowed migration
226 by 20-40 cells to be timed.

227 The zeta potential, ζ i.e. the electrostatic potential at the hydrodynamic shear plane [44], is
228 calculated from the value of the EPM, u by the Helmholtz-Smoluchowski equation:

$$\zeta = \frac{\eta u}{\varepsilon_r \varepsilon_0} \quad (2)$$

229 where ε_r is the relative dielectric constant of the aqueous phase ($\varepsilon_r = 78.5$ at 25°C), η
230 denotes the viscosity of the aqueous phase (25 mM Hepes buffer, 130 mM NaCl, 3.7 mM
231 KCl, 0.25 mM CaCl_2 , pH 7.5; $\eta = 1.21 \pm 0.02$ mPa.s), ε_0 stands for the vacuum
232 permittivity ($\varepsilon_0 = 8.8542 \cdot 10^{-12}$ F.m⁻¹) and EPM is expressed in value $u \cdot 10^8$ m².V⁻¹.s⁻¹. Values
233 represent the mean of three – seven replications. The standard error of mean is between 2 and
234 5 %.

235 The surface electrical charge (σ) reads:

$$\sigma = A^{-1} (C_{ia})^{1/2} \sinh(Z\psi_0/51.38) \quad (3)$$

236 where $A = 1/(8N_A \varepsilon_r \varepsilon_0 T)^{1/2} = 136.6$ at 25°C , $N_A = 6.022 \cdot 10^{23}$ mol⁻¹ is the Avogadro
237 number, $\psi_0 \approx \zeta$; σ expresses in C m⁻² [45].

238 For experiments designed to assess membrane physico-chemical properties, 25 μL of
239 erythrocyte preparation was resuspended in 0.5 mL of Hepes buffered saline to a final density
240 of 4.5×10^6 cells/mL. Erythrocyte suspension was diluted into the 25 mL isotonic Hepes
241 buffered saline tubes containing 2.2×10^6 cells/mL in the EPM measurements. Control
242 erythrocytes contain isotonic Hepes buffered saline devoid of viper toxin.

243

244 *2.7. Lipid peroxidation: Detection of malondialdehyde (MDA) content*

245 The malondialdehyde content was evaluated by analysis of thiobarbituric acid reactive
246 substances (TBARS) [46] with some modifications. Erythrocyte suspension was centrifuged
247 three times at $4500 \times g$ using MiniSpin ® microcentrifuge (Eppendorf, Germany) for 4
248 minutes in 1 mL of the PBS solution at pH 7.4. The pellet was re-suspended with 500 μL PBS
249 solution to Hct 20% and dilutes to 10 mL PBS, pH 7.4, containing 2 mM NaN_3 .
250 Immediately afterwards, 500 μL of erythrocyte suspension was incubated with the

251 corresponding concentration of PLA₂ at 37°C for 5 minutes or 30 minutes, respectively and
252 diluted to 1 mL of the PBS buffer. The sample of erythrocyte suspension without PLA₂
253 represents the control values. The second control with 50 mM H₂O₂ is prepared and the
254 maximal content of lipid peroxidation is registered. In a second set of experiments where the
255 lipid peroxidation of erythrocytes was measured in the presence of fixed doses of 50 nM
256 concentrations of viper toxins. The control sample without viper toxins was incubated at 37
257 °C for an hour in PBS solution, pH 7.4.

258 After incubation of erythrocytes without or in the presence of viper toxin, 0.4 mL of
259 28% trichloroacetic acid was added to the suspension. The following centrifugation at
260 12500×g for 2 min at 4 °C is made. One mL of the reaction mixture and 0.5 mL of 1%
261 thiobarbituric acid were incubated at 95 °C for 30 min. The suspending medium is
262 centrifuged at 12 500×g for 2 min, and the absorbance of λ=532 nm is measured by means of
263 a spectrophotometer Epsilon (Thermo Fischer Scientific Inc., MA, USA) to determine the
264 MDA content. TBARS molar concentration, c , is calculated:

$$c = \frac{A}{\epsilon l} \quad (4)$$

265 where A is the absorbance, ϵ stands for the molar absorption coefficient of H₂O₂, $\epsilon_{532} =$
266 $154000 \text{ M}^{-1}\text{cm}^{-1}$, l represents the optical path length. The lipid peroxidation of
267 erythrocyte membranes is estimated by the production of thiobarbituric acid reactive
268 substances (TBARS) and expressed in M cm^{-1} [46].

269

270 *2.8. Measurements of proton transport and conductivity*

271 The experimental study on the anion-proton co-transport bases on the measurement of net
272 proton flows associated with Band 3-mediated net anion transfer. Erythrocytes suspended in
273 hypotonic sucrose salt-free solution were characterized by the exchange of inorganic anions
274 of chloride and carbonate in connection with the pH equilibration which occurs in minutes.
275 Water transport equilibrates the osmotic gradient in less than one second [19]. A case of
276 “C-state” for erythrocytes is described, where a quasi-stationary state is stable for hours if the
277 membrane permeability is not artificially altered. In the latter processes the osmotic
278 equilibrium, the pH and the anion concentration were equilibrated. The distribution of ions

279 which are in equilibrium with the outside ionic concentrations are described according to the
280 Nernst equation where the activity of the corresponding ion from the interior represents the
281 exponential function of the charge of the ion from the exterior multiplied by the electric
282 potential difference.

283 We measured the extracellular proton concentration (H^+_{ext}) as a function of time in seconds
284 promoted by the treatment of erythrocytes with viper toxin components [47]. The suspending
285 medium of 0.3 M sucrose (NaOH), pH 7.4 was used to maintain its buffer capacity constant
286 over the pH range covered in the experiments [19]. Proton efflux and electrical conductance
287 begin by mixing of 100 μ L of erythrocytes suspended into 50 mL of 0.3 M sucrose (NaOH),
288 pH 7.4. The pH and conductivity of the erythrocyte suspension without or in the presence of
289 different concentrations of viper toxins were measured using a Thermo Fisher Instruments
290 Pte Ltd., (USA/Singapore) pH/conductivity meter.

291 The results for the proton efflux alteration in extracellular media in the presence of different
292 concentrations of toxins is obtained from membrane transport measurements in suspending
293 media every 20 s during 5 minutes at gentle mixing. The value of $\Delta pH(\%)$ is calculated
294 from:

$$\Delta pH = \frac{(pH_o - pH_t)}{pH_o} \times 100$$

295 where pH_o and pH_t are the pH values of erythrocytes in toxin-free medium and in the
296 presence of toxin concentration, respectively. The slope of linear fit ΔpH curve represents
297 the rate of the reaction.

298

299 2.9. Statistical analysis

300 The data obtained in the experiments are expressed as mean \pm SD from the 3-7 independent
301 measurements. The significant means are determined by use of ANOVA after 3 repetitions.

302 The data are analyzed by the use of One-way analysis of variance with
303 Student-Newman-Keuls method for all pairwise comparisons on the mean responses among
304 the different groups taking $p \leq 0.05$ as significant. Dunn's test for all pairwise comparisons

305 and comparisons against a control group following rank-based ANOVA as well as
306 Holm-Sidak test for both pairwise comparisons and comparisons versus a control group was
307 also used.

308

309 3. Results

310 3.1. Osmotic fragility and hematocrit

311 Figure 1 represents the results for the osmotic fragility (OF_{50}) in the presence of fixed
312 concentrations of PLA₂, VAC and Vipoxin, respectively as obtained from osmotic fragility at
313 suspending media with different NaCl concentrations. The value of ΔOF (50%) is
314 calculated:

$$\Delta OF = \frac{(OF_{Vipertoxin} - OF_0)}{OF_0} \times 100$$

315 where $OF_{Vipertoxin}$ and OF_0 are the osmotic fragility of erythrocytes in the presence of
316 the Viper toxin and in Viper toxin-free medium, respectively.

317 Data about hematocrit determination as well as osmotic fragility (OF_{50}) under toxins
318 treatment are characterized by 30 min time period according to the protocols described.
319 After 50 nM PLA₂ treatment, the fragility of erythrocytes increases strongly at 570 nm,
320 where the $H_{50} = 0.7\%$ NaCl is observed ($p=0.002$, Figure 1A). The enhancement in Hct of
321 erythrocytes in the presence of 50 nM PLA₂ compared to control is shown on Figure 1B
322 ($p=0.004$). Vipoxin (50 nM) leads to an increase in OF_{50} at 544 nm ($p=0.002$) without a
323 significant change in Hct. There is change in OF_{50} of erythrocytes treated by 50 nM VAC at
324 544 nm ($p=0.021$).

325

326 3.2. Electrokinetic properties of erythrocytes in the presence of Neuraminidase

327 We test the electrokinetic behaviour of erythrocytes in the presence of neuraminidase (NU)
328 to determine the electrophoretic mobility compared to EPM of untreated erythrocytes. The
329 erythrocyte membranes are treated by neuraminidase (which removes charge bearing sialic
330 acid) for 2 hours at 37 °C. The PLA₂ treatment shows no activity on EPM of erythrocytes

331 under neuraminidase pre-exposure sample compared to control after incubation (2 hours at
332 37 °C), but increases the EPM of PLA₂ treated erythrocytes compared to the control
333 without incubation (Figure 2A). The erythrocytes velocity upon PLA₂ treatment delays in
334 an electric field, while the aggregate complexes of erythrocytes did not allow for
335 measurement due to electrostatic attraction of uncharged surfaces, only the sharply-looking
336 NU-treated erythrocytes were observed and timed (p=0.013).

337 Erythrocyte suspensions without or in the presence of different concentrations of
338 neuraminidase were prepared. Pre-incubated with NU erythrocytes (for 1 h at 37 °C) were
339 treated by PLA₂ at the same conditions as in the case of control human erythrocytes (Figure
340 2B). The results show that after the process of the pre-incubation with NU erythrocytes
341 alter its electrokinetic parameters (electrophoretic mobility and zeta potential) upon PLA₂
342 treatments. It was registered that the treatment by pre-incubation with 30 mU, 40 mU and
343 50 mU neuraminidase the erythrocyte membranes possess lower zeta potential compared to
344 the sample without neuraminidase treatment of erythrocytes after the incubation for 1 h at
345 37 °C (p<0.001, Figure 2B).

346 There was a decrease in zeta potential of erythrocytes upon 25 nM PLA₂ application
347 (p<0.001). A decrease in EPM of erythrocytes pre-incubated with 20 mU NU is
348 characterized by swelling of the cells in the presence of 25 nM PLA₂ in suspending
349 medium. PLA₂ induces aggregation upon pre-incubated with 30 mU NU and aggregate
350 formations of erythrocyte suspension at the first minutes of treatment. There is a settlement
351 of erythrocytes upon 25 nM PLA₂ in neuraminidase pre-incubated erythrocytes due to the
352 structural changes of the membranes. Increasing the concentration of PLA₂ to final
353 concentration of 50 nM PLA₂ leads to a settlement and rupture of erythrocytes and its
354 aggregation after 7 minutes. There is a significant difference in zeta potential of
355 erythrocytes pre-incubated with 30 mU neuraminidase and 50 nM PLA₂ (p<0.001).
356 Exposure of erythrocytes to 40 mU NU causes formation of a different fractions of
357 erythrocytes in suspending medium – smaller cells, swelling and normal discocyte forms.
358 PLA₂ treatment (25 nM) induces swelling of erythrocytes and aggregation in part of them.

359 As previously noted, the aggregated erythrocytes were not measured. Addition of 50 nM
360 PLA₂ induces a less negative EPM of erythrocytes during movement in an electric field,
361 where swelling, lysis and aggregation of part of the cells are observed. Erythrocytes
362 pre-incubated with 40 mU NU show reduction of the zeta potential compared to the control
363 erythrocytes (p<0.001, Figure 2B). Higher concentrations of PLA₂ (80 nM) induce higher
364 zeta potential than the pre-incubated with 40 mU NU cells. Pre-incubated with 50 mU NU
365 erythrocytes possess a decreased EPM compared to the control samples. Swelling of part of
366 the erythrocytes was observed. PLA₂ treatment of pre-incubated with 50 mU NU
367 erythrocytes led to aggregation of some of the spherocytes at the first minute after 25 nM
368 PLA₂ exposure and structural changes could be promoted.

369

370 *3.3. Electrokinetic properties of erythrocytes in the presence of viper toxins*

371 Microelectrophoretic observations show novel results about the electrokinetic properties of
372 erythrocytes during 5-7 minutes measurements of erythrocyte membranes in the presence of
373 viper toxins. The affected cells change their typical shape of biconcave disks to a spherical
374 form. The results show that the disruption follows a 2-3 μm bleb formations changing the
375 organization of the cell structure. The electrostatic effect of PLA₂ is expressed on the
376 erythrocyte membrane. A blebbing effect and large disruptions of the membrane were
377 reported on model lipid membranes [48]. Vipoxin promotes a similar effect to the effect of
378 PLA₂ on the erythrocyte membranes and a blebbing effect at higher concentrations of
379 treatment was observed. Viper toxin components represent multivalent
380 membrane-associating molecules with an 'effective' charge for adsorption to the membrane
381 to proceed at an interface, not within the diffuse ionic double layer. Vipoxin, PLA₂ and
382 VAC have an effective charge of +3.8, +4.3 or of +3.3, respectively in pH 7.5 at ionic
383 strength $I=0.1 \text{ M}^{-1}$ [49].

384 Erythrocytes possess a zeta potential of $\zeta = -20 \text{ mV}$ in isotonic suspending medium. Our
385 results show an enhancement of negative zeta potential with 3.7 mV at 10 nM Vipoxin or at
386 50 nM Vipoxin in suspending medium and a higher increase of 5.5 mV in ζ potential at

387 dose of 100 nM Vipoxin ($p < 0.001$) in comparison to untreated erythrocyte cells (Fig. 3A).
388 We suggest that Vipoxin enhances the magnitude of the negative electrostatic surface
389 potential and increases the electrostatic binding of positively charged residues on its
390 macromolecule to the membrane surface.

391 PLA₂ changes significantly the ζ potential of erythrocyte membranes at concentration of 10
392 – 100 nM of treatment (Fig. 3B). A decrease in zeta potential of erythrocytes upon 50 - 100
393 nM PLA₂ was observed.

394 VAC at 50 nM significantly alters the EPM, zeta potential and surface charge compared to
395 the untreated erythrocyte suspension. Zeta potential of erythrocytes upon the 50 nM VAC
396 treatment possesses values of $\zeta = -28.3$ mV in comparison to the erythrocytes without VAC
397 (Figure 3C). Higher concentration of VAC, 80 nM, reduces the zeta potential ($p = 0.001$) of
398 erythrocyte suspension, compared to the untreated control.

399 Surface electrical charge of erythrocytes is characterized by $\sigma = -0.0264$ C m⁻² in the
400 presence of fixed concentration of 50 nM VAC in suspending medium compared to control
401 sample of $\sigma = -0.0181$ C m⁻² without VAC (Figure 4). Exposure to 50 nM Vipoxin shows
402 a lower value of $\sigma = -0.0211$ C m⁻² than the value of surface charge at the same
403 concentration of VAC in erythrocyte suspension (Figure 4).

404

405 *3.4. Lipid peroxidation of erythrocytes in the presence of the Phospholipase A₂*

406 We studied the hydrogen peroxide content at the plasma membrane of erythrocytes upon
407 viper toxin treatments. Hydrogen peroxide (H₂O₂) is produced endogenously in a number
408 of cellular compartments, including the plasma membrane, where it can play divergent
409 roles as a second messenger or a pathological toxin [50].

410 Phospholipase A₂ concentration ranges from 50 nM – 1000 nM alter lipid peroxidation
411 status of erythrocyte membranes for a longer time of treatment (30 min) ($p < 0.001$). Short
412 time incubation (5 min) of 50 nM – 1000 nM PLA₂ with erythrocytes significantly alters
413 the concentration of free radicals in living cells (Figure 5A, $p < 0.001$), differentially. There
414 is a strong increase in TBARS values of erythrocytes in the presence of 50 nM PLA₂ for

415 both times of incubation. The reduction of lipid peroxidation of erythrocyte membranes is
416 determined with increasing the dose of treatment with PLA₂ for shorter time of incubation.
417 Doses of 100 nM PLA₂ and 1000 nM PLA₂ in erythrocyte suspension induce a maximal
418 enhancement of TBARS levels after 30 min time of incubation.

419 A reduction of the lipid peroxidation of erythrocytes upon fixed concentrations of 50 nM
420 Vipoxin, PLA₂ and VAC was observed (Figure 5B). The 50 nM PLA₂ has no effect on lipid
421 peroxidation of erythrocytes compared to the TBARS value of untreated erythrocyte
422 membranes. VAC and Vipoxin decreased the lipid peroxidation levels of erythrocyte
423 suspension by a similar extent (p=0.007) in comparison to the TBARS of control
424 erythrocytes without VAC or Vipoxin, respectively. Lipid peroxidation of erythrocyte
425 membranes in the presence of 50 mM H₂O₂ showed highest value of 1.1 μM TBARS after
426 1 h incubation of erythrocytes compared to control- viper toxin free-treated cells.

427

428 *3.5. Membrane transport and conductivity measurements*

429 Membrane transport test monitors the proton efflux from the erythrocytes suspended in
430 sucrose salt-free medium. Extracellular proton concentration (H⁺_{ext}) as a function of time is
431 changed by the treatment of erythrocytes by viper toxin components. Figures 6 (A,B) and 7
432 (A,B) represent the results for the proton efflux alteration in extracellular media in the
433 presence of different concentrations of toxins as obtained from membrane transport
434 measurements in suspending media every 20 seconds during 5 minutes at gentle mixing.
435 Figures 6 (C,D) and 7 (C,D) describe the conductivity of erythrocyte suspension in the
436 presence of viper toxins.

437 PLA₂ induces an increase in the slope of the linear fit curve of ΔpH (10 – 60 nM) (Figure
438 6B) and the slope of conductivity linear fit at dose of 20 nM (Figure 6D). In order to study
439 the mechanism of interaction of fixed concentrations of 50 nM viper toxins with
440 erythrocyte membranes, the ΔpH measurements were performed at different times. The
441 maximum value of the proton concentration in extracellular space of erythrocytes in the
442 presence of 50 nM PLA₂ is reported on Figure 7B. A dose of 50 nM PLA₂ slightly changed

443 the H⁺ efflux, but strongly altered the conductivity of erythrocyte suspension. A strong
444 increase in the slope of conductivity of erythrocyte suspension upon basic Vipoxin
445 component was measured (Figure 7D).

446 VAC induces a decrease in the slope of the linear fit curve and lower value of the proton
447 concentration in extracellular space in erythrocytes due to the lower pI of the acidic
448 component in comparison to the control kinetic curve (Figure 7B). VAC increases the H⁺
449 efflux up to 140 s after beginning of the membrane transport registration, but accompanied
450 by a strong enhancement of conductivity in all times measured (Figure 7D).

451 Vipoxin inhibits the slope of linear fit curve of Δ pH registration up to 20 s, after that the
452 processes of transport of protons is characterized without changes in the H⁺ efflux but
453 increases the conductivity of the erythrocyte suspension compared to control values (Figure 7
454 B, D).

455

456 **4. Discussion**

457 Viper toxins strongly affect the membrane characteristics of erythrocytes. The reported
458 biomacromolecules are of deep interest under various pathophysiological conditions. In the
459 present study, we investigate the interaction of viper toxins with erythrocyte membranes the
460 using the electrokinetic approach. VAC and Vipoxin both possess similar effective
461 electrical charges on their molecules and induce an increase in negative surface electrical
462 charges on the erythrocyte membrane due to an electrostatic interaction with erythrocyte
463 membranes. In our experiments we use low treatment concentrations of viper toxins in
464 order to prevent aggregation of erythrocytes due to disruption of cells and following
465 sedimentation of erythrocytes during microelectrophoretic measurements at 52 nM PLA₂ in
466 suspending medium. Higher concentrations of PLA₂ decrease the zeta potential of the
467 erythrocytes due to the effect of Ca²⁺ in suspension medium on the activity of PLA₂. Zeta
468 potential of human erythrocytes increases with increasing Vipoxin concentration promoted
469 by their binding to the membrane. More negatively charged surface by Vipoxin and VAC
470 treatments on the outer surface of the erythrocyte membrane determines the higher surface
471 electric charge where electrostatic forces of repulsion dominate over attraction between the

472 erythrocytes. The upper effect is due to the contribution of Band 3 negative charges on the
473 dimeric interface of the membrane upon viper toxin treatments on the erythrocytes [21].

474 Our results show that neuraminidase pre-treated erythrocytes do not change their
475 electrokinetic properties, evoked by the PLA₂. Neuraminidase diminishes the net surface
476 charge of the membrane and ζ potential values of erythrocytes do not change appreciably
477 when treated with various toxins. The untreated erythrocytes possess lower net negative
478 charge compared to erythrocytes incubated with neuraminidase for an hour at 37 °C. Our
479 results show that neuraminidase does not exhibit a hemolysis of erythrocytes. Despite the
480 action of PLA₂ on erythrocytes for longer time of incubation, NU pre-incubation causes an
481 increase in EPM and zeta potential on the membrane. Hence, the sialic acid residues are not
482 the main factor in determining the electrokinetic properties of erythrocyte membrane upon
483 PLA₂ action on the membrane. The externalization of the negatively charged phospholipids
484 from the inner membrane due to formation of products of the phospholipase reaction upon
485 viper toxin application results from the local damage of the membrane. The phospholipase
486 A₂ activity is increased in vesicles containing oxidized soybean phosphatidylcholine
487 compared that the activity in non-oxidized phospholipid membranes [51]. According
488 reports of Litvinko et al. [52] PLA₂ does not act on the tightly packed lipid bilayers. The
489 exposure of additional negative charged groups of the proteins and lipids on the surface of
490 erythrocytes because of conformational changes and re-organization of membrane
491 components explains the higher net surface charge of erythrocyte membrane upon viper
492 toxin treatment.

493 The interactions of anionic phospholipids and cholesterol and specific sites of Band 3 are
494 situated at the dimeric interface forming an annulus around the protein. The upper strong
495 interactions may play a role in folding and function of this anion transport membrane
496 protein [21]. PLA₂ influences the membrane transport and conductivity of erythrocyte
497 suspension. Lower concentration of PLA₂ (1 nM) leads to a reduction of the rate of proton
498 efflux. It is demonstrated in an indirect relationship with the inhibition of membrane
499 transport at the side of the transmembrane protein of Band 3 for proton and H⁺ /Cl⁻

500 cotransport across the erythrocyte membrane without changes in conductivity. On the
501 contrary, higher concentrations of PLA₂ (20-60 nM) had no alteration on the
502 anion-exchange function of Band 3, without change in H⁺ efflux, but with a strong increase
503 in conductivity of erythrocyte suspension. PLA₂ promotes an enhancement of the
504 concentration and mobility of the ions in erythrocyte suspension without changing the
505 proton efflux at 20-60 nM doses due to an increased production of free radicals, especially
506 lipid peroxides. There is a higher MDA content of erythrocyte membrane in the presence of
507 50-100 nM PLA₂ for a short time of incubation compared to the untreated erythrocytes.

508 Fixed concentrations of 50 nM PLA₂ induce an increase in the rate of the proton efflux
509 through the membrane and strong enhancement of the conductivity of erythrocyte
510 suspension. The VAC leads to a strong reduction in the rate of the proton efflux and
511 increase in conductivity perhaps by restricting the conformational change in Band 3 that
512 occurs during transport. VAC induces more negatively charged groups of the C-terminal
513 membrane domain of Band 3 to be exposed and follows a large enhancement of net surface
514 charge. In the case of 50 nM VAC treatment an increase in negative charges on the
515 membrane surface is a result of the electrostatic interaction of its macromolecules with
516 negatively charged membranes leading to Van der Waals repulsive forces between the
517 VAC-treated erythrocytes. The fixed doses of 50 nM Vipoxin causes the higher surface
518 electrical charge and conductivity because of the reduction in the rate of the H⁺ efflux in the
519 extracellular space.

520 The significant change in the electrokinetic potential of erythrocytes is accompanied by a
521 strong increase in lipid peroxidation upon 30 min incubation with PLA₂. We observe that
522 increasing concentration of PLA₂ promotes more TBARS products in human erythrocytes.
523 The Vipoxin electrostatic interaction has similar effect on erythrocyte membrane (as in the
524 case of PLA₂) where a blebbing effect in higher concentrations of treatment is viewed [48].
525 VAC and Vipoxin enhance the net surface charge density of erythrocyte membranes and
526 decrease the lipid peroxidation of the membranes at fixed 50 nM dose.

527 Viper toxins alter the passive electrical properties of the membrane. The anion-exchange
528 function of Band 3 is altered with enhancement in proton transport and conductivity of
529 erythrocytes by PLA₂ and Vipoxin treatments. VAC induces an increase in surface
530 electrical charge due to increase in conductivity through the membrane, but reduces the
531 proton efflux because of low pI=4.3 of the macromolecules. The reported results open
532 perspectives to a further investigation of the surface electrical charge of the membrane after
533 viper toxins treatment to shed light on the molecular mechanisms driving the mechanisms
534 of inflammation and neurodegenerative diseases.

535

536 **5. Conclusion**

537 Microelectrophoresis approach allows for the following conclusions on the effects of
538 purified components of Vipoxin on the electrokinetic potential of erythrocytes to be
539 reported: (i) No significant change of the surface electrical charge and strong increase in
540 osmotic fragility (570 nm) upon 50 nM PLA₂ dose. (ii) Increased stability of the system in
541 the presence of 50 nM VAC or 50 nM Vipoxin due to exposure of additional negative
542 charges at dimeric interface of Band 3 of the membrane; (iii) The electrokinetic potential of
543 erythrocytes upon 50 nM of VAC or Vipoxin treatment showed that the viper components
544 are used for causing higher net negative electrical charges on the erythrocyte surface
545 impeding the process of aggregation of the cells due to a higher osmotic fragility (544 nm).

546 This broadens the perspectives of biomacromolecules research using a novel
547 physico-chemical properties of the erythrocyte membrane and points out the role of VAC
548 and Vipoxin in the enhancement of stability of the cells for time before erythrocyte
549 aggregation.

550 The protective effect of lower doses of viper toxins observed by the lipid peroxidation of
551 erythrocytes relates to the non-specific electrostatic interactions. The reported results open
552 new perspectives to further investigation of the role of the type of lipids and lipid domains
553 on the peroxidation related processes in viper toxin-exposed erythrocytes with the purpose
554 of clarifying the molecular mechanisms driving its protective role.

555 Viper toxins accelerate the proton efflux and conductivity in the erythrocyte suspension
556 following the effectiveness line: PLA₂>Vipoxin>VAC. By providing knowledge on the
557 proton transport through Band 3 of the erythrocyte membranes in the presence of viper
558 toxins the reported results may serve for clarifying the mechanism of its biologically active
559 action.

560

561 **Conflict of interest**

562 No conflicts of interest to report.

563

564 **Author contributions**

565 V. D. – conceptualization, methodology, validation, formal analysis, investigation, data
566 curation, visualization, writing- original draft preparation, review and editing, project
567 administration, P. R. A. – validation, formal analysis, visualization, writing - original draft
568 preparation, review and editing, S. P. S. – reviewing the manuscript .

569

570 **Acknowledgments**

571 This work was supported by the Bulgarian National Fund of Scientific Research (Grant
572 KP-06-N38/14/2019). The authors thanks for the generous gift of vipoxin and its separated
573 components from Prof. Dr. S. D. Petrova.

574

575

576 **Abbreviations**

577 EPM– electrophoretic mobility;

578 ζ– electrokinetic (zeta) potential;

579 σ– surface charge density (surface electrical charge);

580 æ – electrical conductivity;

581 HEPES– N-(2-Hydroxyethyl) piperazine-N'-(2-ethanesulfonic acid);

582 PBS– phosphate – buffered saline;

583 PLA₂– phospholipase A₂ (Vipoxin basic component);

584 VAC – Vipoxin acidic component;

585 NU – neuraminidase;

586 Hct – hematocrit;

587 OF – osmotic fragility;

588 MDA– malondialdehyde;

589 TBA– 2-thiobarbituric acid;

590 TBARS– thiobarbituric acid reactive substances.

591

592 **References**

593

594 [1] A. Ramamoorthy, S. Thennarasu, D-K. Lee, A. Tim, L. Maloy, Solid state NMR
595 investigation of the membrane-disrupting mechanism of Antimicrobial Peptides MSI-78
596 and MSI-594 derived from magainin 2 and melittin, Biophysical Journal, 91 (2006)
597 206-216, doi: 10.1529/biophysj.105.073890.

598 [2] A. Bhunia, P.N. Domadia, S. Bhattacharjya, Structural and thermodynamic analyses of
599 the interaction between melittin and lipopolysaccharide, Biochimica et Biophysica Acta,
600 1768 (2007) 3282-3291, doi:10.1016/j.bbamem.2007.07.017.

601 [3] J. Hong, X. Lu, Z. Deng, S. Xiao, B. Yuan, K. Yang, How melittin inserts into cell
602 membrane: Conformational changes, inter-peptide cooperation, and disturbance on the
603 membrane, Molecules, 24 (2019) 1775, doi: 10.3390/molecules24091775.

604 [4] M.C. de Araujo Melo, C.G. Rodrigues, L. Pol-Fachin, *Staphylococcus aureus* δ -toxin in
605 aqueous solution: Behaviour in monomeric and multimeric states, Biophysical Chemistry,
606 227 (2017) 21-28, <http://doi.org/10.1016/j.bpc.2017.05.015>.

607 [5] M.N. Karemore, J.G. Avari, Alteration in zeta potential of erythrocytes in preeclampsia
608 patients, Nidhi Sharma, IntechOpen.85952, doi:10.5772/intechopen.85952.

- 609 [6] H.P. Fernandes, C.L. Cesar, M.L. Barjas-Castro, Electrical properties of the red blood
610 cell membrane and immunohematological investigation, *Revista Brasileira de*
611 *Hematologia e Hemoterapia*, 33(4) (2011) 297-301, doi:10.5581/1561-8484-20110080.
- 612 [7] V.V. Revin, N.V. Gromova, E.S. Revina, M.I. Martynova, A.I. Seikina, N.V. Revina,
613 O.G. Imarova, I.N. Solomadin, A.Yu. Tychkov, N. Zhelev, Role of membrane lipids in the
614 regulation of erythrocytic oxygen-transport function in cardiovascular diseases, *BioMed*
615 *Research International*, vol. 2016 (2016), article ID 3429604,
616 <http://dx.doi.org/10.1155/2016/3429604>.
- 617 [8] C. Leonard, H. Pollet, C. Vermylen, N. Gov, D. Tyteca, M-P. Mingeot-Leclecq,
618 Tuning of differential order between submicrometric domains and surrounding membrane
619 upon erythrocyte reshaping, *Cell Physiology and Biochemistry*, 48 (2018) 2563-2582,
620 doi:10.1159/000492700.
- 621 [9] R.H. Fang, B.T. Luk, C-M J. Hu, L. Zhang, Engineered nanoparticles mimicking cell
622 membranes for toxin neutralization, *Advanced Drug Delivery Reviews*, 90 (2015) 69-80,
623 doi:10.1016/j.addr.2015.04.001.
- 624 [10] R.A. Campbell, E.B. Watkins, V. Jagalski, A. Åkesson-Runnsjö, Key Factors
625 Regulating the Mass Delivery of Macromolecules to Model Cell Membranes: Gravity and
626 Electrostatics, *ACS Macro Letters*, 3(2) (2014) 121-125,
627 <https://doi.org/10.1021/mz400551h>.
- 628 [11] R.M. Kini, Excitement ahead: structure, function and mechanism of snake venom
629 phospholipase A2 enzymes, *Toxicon*, 42 (2003) 827-840,
630 doi:10.1016/j.toxicon.2003.11.002.
- 631 [12] C.Y. Koh, R.M. Kini, From snake venom toxins to theurapeutics-cardiovascular
632 examples, *Toxicon*, 59(4) (2012) 497-506, doi:10.1016/j.toxicon.2011.03.017.
- 633 [13] S.L. Da Silva, E.G. Rowan, F. Albericio, R.G. Stábeli, L.A. Calderon, A.M. Soares,
634 Animal toxins and their advantages in biotechnology and pharmacology, *BioMed Research*
635 *International*, 2014 (2014) Art No ID 951561, <https://doi.org/10.1155/2014/951561>.

- 636 [14] N. Chen, S. Xu, Y. Zhang, F. Wang. Animal protein toxins: origin and therapeutic
637 applications, *Biophysics Reports*, 4(5) (2018) 233-242,
638 <https://doi.org/10.1007/s41048-018-00667-x>.
- 639 [15] A.M. Soares, J.P. Zuliani, Toxins and animal venoms and inhibitors: Molecular and
640 biotechnological tools useful to human and animal health, *Current Topics in Medicinal*
641 *Chemistry*, 19(21) (2019) 1868-1871, doi:10.2174/156802661921191024114842.
- 642 [16] K. Balashev, V. Atanasov, M. Mitewa, S. Petrova, T. Bjørnholm, Kinetics of
643 degradation of dipalmitoylphosphatidylcholine (DPPC) bilayers as a result of vipoxin
644 phospholipase A2 activity: an atomic force microscopy (AFM) approach, *Biochimica et*
645 *Biophysica Acta* 1808(1) (2011) 191-198, <http://dx.doi.org/10.1016/j.bbamem.2010.10.008>.
- 646 [17] S.D. Petrova, V.N. Atanasov, K. Balashev, Vipoxin and its components: structure
647 –function relationship, in Ch. Z. Christov, T. Karabancheva-Christova (Eds.), *Advances in*
648 *Protein Chemistry and Structural Biology*, vol. 87, *Structural and Mechanistic*
649 *Enzymology: Bringing together experiments and computing*, Academic Press, San Diego,
650 USA, 2012, pp. 117-155.
- 651 [18] J. Dumanov, K. Mladenova, T. Topouzova-Hristova, S. Stoitsova, S. Petrova,
652 Effects of vipoxin and its components on HepG2 cells, *Toxicon*, 94 (2015) 36-44,
653 <http://dx.doi.org/10.1016/j.toxicon.2014.12.009>.
- 654 [19] R. Glaser, J. Donath, Stationary ionic states in human red blood cells,
655 *Bioelectrochemistry and Bioenergetics*, 13 (1984) 71-83.
- 656 [20] S.E. Lux, K.M. John, R.R. Kopito, H.F. Lodish, Cloning and characterization of
657 band 3, the human erythrocyte anion-exchange protein (AE1), *Proceedings of the National*
658 *Academy of Sciences USA*, 86 (1989) 9089-9093, <https://doi.org/10.1073/pnas.86.23.9089>
- 659 [21] A.C. Kalli, R.A.F. Reithmeier, Interaction of the human erythrocyte Band 3 anion
660 exchanger 1 (AE1, SLC4A1) with lipids and glycophorin A: Molecular organization of the
661 Wright (Wr) blood group antigen, *PLoS Computational Biology*, 14(7) (2018) e1006284,
662 <https://doi.org/10.1371/journal.pcbi.1006284>.

- 663 [22] E. Taşkin, S. Çelik, D.M. Yavuz, F. Kara, Investigation of relationship between
664 erythrocyte sedimentation rate and erythrocyte indices, *Kafkas Journal of Medical*
665 *Sciences*, 9(2) (2019) 87-89, doi:10.5505/kjms.2019.67934.
- 666 [23] A. Valadão Cardoso, An experimental erythrocyte rigidity index (R_i) and its
667 correlations with Transcranial Doppler velocities (TAMMV), golling Pulsatility Index PI,
668 hematocrit, hemoglobin concentration and red cell distribution width (RDW), *PLoS ONE*
669 15(2) (2020) e0229105, <https://doi.org/10.1371/journal.pone.0229105>.
- 670 [24] B. Tchorbanov, E. Grishin, B. Alexiev, Y. Ovchinnikov, A neurotoxic complex
671 from the venom of the Bulgarian viper (*Vipera ammodytes ammodytes*) and partial amino
672 acid sequence of the toxic phospholipase A₂, *Toxicon* 16(1) (1978) 37-44,
673 doi:10.1016/0041-0101(78)90058-2.
- 674 [25] D.A. Six and E.A. Dennis, The expanding superfamily of phospholipase A₂
675 enzymes: classification and characterization, *Biochimica et Biophysica Acta* 1488(1-2)
676 (2000) 1-19, doi:10.1016/s1388-1981(00)00105-0.
- 677 [26] E.A. Dennis, J. Cao, Y-H. Hsu, V. Magrioti, G. Kokotos, Phospholipase A₂
678 enzymes: physical structure, biological function, disease implication, chemical inhibition,
679 and therapeutic intervention, *Chemical Reviews*, 111(10) (2011) 6130-6185,
680 doi:10.1021/cr200085w.
- 681 [27] D.N. Georgieva, N. Genov, K.R. Rajashankar, B. Aleksiev, C. Betzel, Spectroscopic
682 investigation of phenolic groups ionization in the vipoxin neurotoxic phospholipase A₂:
683 Comparison with the X-ray structure in the region of the tyrosyl residues, *Spectrochimica*
684 *Acta Part A*, 55(1999) 239-244.
- 685 [28] T. Matsui, S. Kamata, K. Ishii, T. Maruno, N. Ghanem, S. Uchiyama, K. Kato, A.
686 Suzuki, N. Oda-Ueda, T. Ogawa, Y. Tanaka, SDS-induced oligomerization of
687 Lys49-phospholipase A₂ from snake venom, *Scientific Reports*, 9 (2019) 2330,
688 <https://doi.org/10.1038/s41598-019-38861-8>.
- 689 [29] T.W. Yau, R.P. Kuchel, J.M.S. Koh, D. Szekely, P.W. Kuchel, Cytoskeletal
690 rearrangements in human red blood cells induced by snake venoms: light microscopy of

691 shapes and NMR studies of membrane function, *Cell Biology International*, 36 (2012)
692 87-97, doi:10.1042/CBI20110012.

693 [30] S. Banumathi, K.R. Rajashankar, C. Nöetzel, B. Alexiev, T.P. Singh, N. Genov, C.
694 Betzel, Structure of the neurotoxic complex vipoxin at 1.4 Å resolution, *Acta*
695 *Crystallographica Section D: Structural Biology*, 57(Pt 11) (2001) 1552-1559,
696 doi:10.1107/s0907444901013543.

697 [31] Y. Devedjiev, A. Popov, B. Atanasov, H.D. Bartunik, X-ray structure at 1.76 Å
698 resolution of a polypeptide phospholipase A₂ Inhibitor, *Journal of Molecular Biology*, ,
699 266(1) (1997) 160-72, doi:10.1006/jmbi.1996.0778.

700 [32] M. Perbandt, J.C. Wilson, S. Eschenburg, I. Mancheva, B. Aleksiev, N. Genov, P.
701 Willingmann, W. Weber, T.P. Singh, Ch. Betzel, Crystal structure of vipoxin at 2.0 Å: an
702 example of regulation of a toxic function generated by molecular evolution, *FEBS Letters*,
703 412 (1997) 573-577, [https://doi.org/10.1016/S0014-5793\(97\)00853-3](https://doi.org/10.1016/S0014-5793(97)00853-3).

704 [33] C. Keith, D.S. Feldman, S. Deganello, J. Glick, K.B. Ward, E.O. Jones, P.B.
705 Sigler, The 2.5 Å crystal structure of a dimeric phospholipase A₂ from venom *Crotalus*
706 *atrox*, *Journal of Biological Chemistry*, 256 (1981) 8602-8607.

707 [34] J.E. Freedman, S.H. Snyder, Vipoxin A protein from Russell's viper venom with
708 high affinity for biogenic amine receptors, *Journal of Biological Chemistry*, 256 (24)
709 (1981) 13172-13179.

710 [35] K.A. Runas, N. Malmstadt, Low levels of lipid oxidation radically increase the
711 passive permeability of lipid bilayers, *Soft Matter*, 11 (2015) 499-505,
712 <https://doi.org/10.1039/C4SM01478B>.

713 [36] A. Ayala, M.F. Muñoz, S. Argüelles, Lipid peroxidation: Production, metabolism,
714 and signalling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal, *Oxidative*
715 *medicine and Cellular Longevity*, vol.2014 (2014), Article ID 360438,
716 <https://dx.doi.org/10.1155/2014/360438>.

717 [37] C. Pertibois, G. Dél  ris, Evidence that erythrocytes are highly susceptible to exercise
718 oxidative stress: FT-IR spectrometric studies at the molecular level, *Cell Biology*
719 *International*, 29(8) (2005) 709-716, <https://doi.org/10.1016/j.cellbi.2005.04.007>.

720 [38] T.M. Tsubone, M.S. Baptista, R. Itri, Understanding membrane remodelling initiated
721 by photosensitized lipid oxidation, *Biophysical Chemistry*, 254 (2019) 106263,
722 <https://doi.org/10.1016/j.bpc.2019.106263>.

723 [39] P.K. Smith, R.I. Krohn, G.T. Hermanson, A.K. Mallia, F.H. Gartner, M.D.
724 Provenzano, E.K. Fujimoto, N.M. Goetze, B.J. Olson, D.C. Klenk, Measurement of protein
725 using bicinchoninic acid, *Analytical Biochemistry*, 150 (1985) 76-85,
726 [doi:10.1016/0003-2697\(85\)90442-7](https://doi.org/10.1016/0003-2697(85)90442-7).

727 [40] I. Mancheva, T. Kleinschmidt, B. Alexiev, G. Braunitzer, Sequence homology
728 between phospholipase and its inhibitor in snake venom. The primary structure of
729 phospholipase A₂ of vipoxin from the venom of the Bulgarian viper (*Vipera ammodytes*
730 *ammodytes*, *Serpentes*), *Biological Chemistry Hoppe Seyler*, 368 (1987) 343-352,
731 [doi:10.1515/bchm3.1987.368.1.343](https://doi.org/10.1515/bchm3.1987.368.1.343).

732 [41] B. Tchorbanov, B. Alexiev, A simple procedure for the isolation of Vipoxin – a
733 neurotoxin with phospholipase A₂ activity from the venom of the Bulgarian viper (*Vipera*
734 *ammodytes*), *Journal of Applied Biochemistry*, 3 (1981) 558-561.

735 [42] J. Rifkind, K. Araki, E. Hadley, The relationship between the osmotic fragility of
736 human erythrocytes and cell age. *Archives in Biochemistry and Biophysics*, 222 (1983)
737 582-589, [doi:10.1016/0003-9861\(83\)90556-8](https://doi.org/10.1016/0003-9861(83)90556-8).

738 [43] F. Men, A.I. Alayash, Determination of extinction coefficients of human
739 hemoglobin in various redox states, *Analytical Chemistry*, 521(2017) 11-19,
740 [doi:10.1016/j.ab.2017.01.002](https://doi.org/10.1016/j.ab.2017.01.002).

741 [44] G.M. Barrow, *Physical Chemistry*. 1996, McGraw – Hill: Boston, Massachusetts.

742 [45] S. McLaughlin, Electrostatic Potentials at membrane-solution interfaces, *Current*
743 *Topics in Membranes and Transport*, 9 (1977) 71-144.

744 [46] B. Halliwell, J.M. Gutteridge, in B. Halliwell and J.M.C Gutteridge (Eds.), Free
745 Radicals in Biology and Medicine, 1999. 3rd Edition, Oxford University Press, Oxford: p.
746 1-25.

747 [47] S. Lepke, J. Heberle, H. Passow, 10 The Band 3 protein: Anion exchanger and
748 anion-proton cotransporter, in I. Bernhardt, J.C. Ellory (Eds.), Red cell membrane transport
749 in health and disease, Springer, 2003, pp. 221-252.

750 [48] R. Georgieva, K. Mircheva, V. Vitkova, K. Balashev, T. Ivanova, C. Tessier, K.
751 Koumanov, P. Nuss, A. Momchilova, G. Staneva, Phospholipase A2-Induced Remodeling
752 Processes on Liquid-Ordered/Liquid-Disordered Membranes Containing Docosahexaenoic
753 or Oleic Acid: A Comparison Study, Langmuir 32(7) (2016) 1756-1770,
754 doi:10.1021/acs.langmuir.5b03317.

755 [49] S. Stankowski, Surface charging by large multivalent molecules. Extending the
756 standard Gouy-Chapman treatment, Biophysical Journal. 60(2) (1991) 341-351,
757 doi:10.1016/S0006-3495(91)82059-8.

758 [50] Y-X. Huang, Z-J Wu, J. Mehrishi, B-T Huang, X-Y Chen, X-J Zheng, W-J Liu, M.
759 Luo, Human red blood cell aging: correlative changes in surface charge and cell properties,
760 Journal of Cellular and Molecular Medicine, 15(12) (2011) 2634-2642,
761 doi:10.1111/j.1582-4934.2011.01310.x.

762 [51] M.G. Salgo, F.P. Corongui, A. Sevanian, Enhanced interfacial catalysis and
763 hydrolytic specificity of phospholipase A1, Archives of Biochemistry and Biophysics, 304
764 (1993) 123-132.

765 [52] N.M. Litvinko, L.A.Skorosteskaya, D.O. Gerlovsky, The interaction of
766 phospholipase A₂ with oxidized phospholipids at the lipid-water surface with different
767 structural organization, Chemistry and Physics of Lipids, 211(2018) 44-51.
768
769
770
771
772

773 **Figure Legends**

774

775 **Figure 1. Osmotic fragility of erythrocytes in the presence of viper toxins.** (A) Osmotic
776 fragility changes in erythrocytes in the presence of fixed concentrations of PLA₂, VAC and
777 Vipoxin after incubation *in vitro* in NaCl solutions. Control samples contain saline instead
778 of the toxin (0% hemolysis). (B) Effect of fixed concentrations of 50 nM of PLA₂, VAC
779 and Vipoxin treatments on Hematocrit (average value \pm SD of 5-7 independent repetitions,
780 3 independent experiments) of erythrocytes suspended in PBS, pH 7.4. Values of $p < 0.05$
781 are considered significant.

782

783 **Figure 2. Electrokinetic properties of erythrocytes in the presence of Neuraminidase.**
784 (A) Erythrocytes incubation without or in the presence of neuraminidase (NU) for 2 h at 37
785 °C. C_0 – electrophoretic mobility (EPM) of control erythrocytes, measured immediately
786 after washing of erythrocytes; C_1 – EPM of erythrocytes incubated for an hour without
787 neuraminidase in Hepes buffered saline (25 mM Hepes, 130 mM NaCl, 3.7 mM KCl, 0.25
788 mM CaCl₂, pH 7.5); EPM of erythrocytes after 25 nM PLA₂ treatment without or in the
789 presence of 10 mU and 20 mU neuraminidase, respectively; EPM of erythrocytes upon
790 different concentrations of neuraminidase treatment (30 mU, 40 mU and 50 mU NU) in the
791 presence of 50 nM, 80 nM and 100 nM PLA₂, respectively. The data are expressed as mean
792 \pm SD. Values of $p < 0.05$ are considered significant. * $p = 0.02$ or $p = 0.013$, compared to the
793 untreated control. (B) Zeta potential of erythrocytes after pre-incubation upon treatment at
794 different concentrations of neuraminidase (NU). C_{60} – ζ potential of erythrocytes incubated
795 for an hour without neuraminidase in Hepes buffered saline (25 mM Hepes, 130 mM NaCl,
796 3.7 mM KCl, 0.25 mM CaCl₂, pH 7.5); Erythrocytes are pre-incubated with neuraminidase
797 (NU) at 1 h at 37 °C; Influence of PLA₂ treatments as followed: 10 mU NU + 25 nM PLA₂;
798 20 mU NU + 25 nM PLA₂; 30 mU NU + 50 nM PLA₂; 40 mU NU + 80 nM PLA₂; 50 mU
799 + 100 nM PLA₂. ζ potential of erythrocytes upon upper NU treatments in the presence of
800 different concentrations of PLA₂ exposure. Values of $p < 0.05$ are considered significant.
801 *** $p < 0.001$, compared to the control without NU.

802

803 **Figure 3. Zeta potential of erythrocytes in the presence of viper toxins.** Zeta potential
804 of human erythrocytes upon Vipoxin (A), PLA₂ (B) and VAC (C) treatments. Medium
805 contains Hepes buffered saline. Data are means \pm SD of three - seven independent
806 experiments. *** $p < 0.001$, compared to the control without viper toxins.

807

808 **Figure 4. Surface electrical charge of erythrocytes in the presence of viper toxins.**
809 Surface electrical charge of erythrocytes in the presence of 50 nM of phospholipase A₂
810 (PLA₂), 50 nM Vipoxin acidic component (VAC) and 50 nM Vipoxin in suspending

811 medium of Hepes buffered saline. Values of each group present the mean \pm SD of 5
812 independent experiments. *** $p < 0.001$, compared to the untreated control.

813

814 **Figure 5. Lipid peroxidation of erythrocytes in the presence of viper toxins.** Lipid
815 peroxidation in erythrocytes as a function of different concentrations of (A) phospholipase
816 A₂ (PLA₂); Data are expressed as mean \pm SD, 3 independent measurements with $n = 3$
817 repetitions. *** $p < 0.001$, compared to the control samples without PLA₂. (B) Fixed
818 concentrations of 50 nM of Phospholipase A₂, Vipoxin acidic component (VAC) and
819 Vipoxin; Values of $p < 0.05$ are considered significant. Suspending medium consists of
820 phosphate buffered saline (PBS). The second control of 50 mM H₂O₂ represents the
821 maximal value of TBARS products in dependence of time of incubation (A: 5 min or 30
822 min at 37 °C; B: 1 hour at 37 °C).

823

824 **Figure 6. H⁺-Cl⁻ co-transport and conductivity in erythrocytes containing PLA₂.** (A)
825 Extracellular proton concentration (H⁺_{ext}) as a function of time (s), calculated from the
826 recorded Δ pH changes induced by sudden jumps of the extracellular proton concentration of
827 erythrocytes in Sucrose, salt-free medium (NaOH), pH 7.4, in the presence of different
828 concentrations of PLA₂. (B) The initial slopes of linear fit curve of Δ pH changes in
829 erythrocyte membranes without or in the presence of different doses of PLA₂. (C)
830 Conductivity measurements as a function of time (s) in erythrocytes suspended in Sucrose,
831 salt-free medium (NaOH), pH 7.4, in the presence of different concentrations of PLA₂. (D)
832 The initial slopes of linear fit curve of Δ κ changes in erythrocyte membranes without or in
833 the presence of different doses of PLA₂.

834

835 **Figure 7. H⁺-Cl⁻ co-transport and conductivity in erythrocytes containing viper**
836 **toxins.** (A) Extracellular proton concentration (H⁺_{ext}) as a function of time (s), calculated
837 from the recorded Δ pH changes induced by sudden jumps of the extracellular proton
838 concentration of erythrocytes in Sucrose, salt-free medium (NaOH), pH 7.4, in the presence
839 of fixed concentrations of 50 nM PLA₂, 50 nM VAC and 50 nM Vipoxin, respectively. (B)
840 The initial slopes of linear fit curve of Δ pH changes in erythrocyte membranes without or in
841 the presence of fixed concentrations of 50 nM doses of viper toxins. (C) Conductivity
842 measurements as a function of time (s) in erythrocytes suspended in Sucrose, salt-free
843 medium (NaOH), pH 7.4, in the presence of fixed concentrations of 50 nM PLA₂, 50 nM
844 VAC and 50 nM Vipoxin, respectively. (D) Initial slopes of linear curve fit of Δ κ changes in

845 erythrocyte membranes without or in the presence of fixed concentrations of 50 nM doses of
846 viper toxins.

847

848 **Supplementary Figure 1. Protein components of neurotoxin, isolated from *Vipera***
849 ***ammodytes meridionalis*.** (A) Electrophoretic analysis of protein components in 12%
850 polyacrylamide gel under non-reducing conditions (*Vipera ammodytes meridionalis* venom).
851 Profiles of the protein fractions are presented. M – marker. (B) Immunoblot from control and
852 experimental mouse animals after Vipoxin treatment – neurotoxin isolated from *Vipera*
853 *ammodytes meridionalis*: VAC – Vipoxin acidic component, M – Marker, PLA2 –
854 phospholipase A2, NT – untreated animal). A reaction is found in the brain of all animals
855 where the untreated (NT) and treated with *Vipera ammodytes meridionalis* venom are
856 noticed at a level of ~28 kDa, which is the Mr of Vipoxin.

857

858 **Figures**

859

860

861

862

863

864

865

866

867

868

869

870

871

872

873

874

875

876

877




Figure 1

878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910




Figure 2

911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943




Figure 3




Figure 4

977
 978
 979
 980
 981
 982
 983
 984
 985
 986
 987
 988
 989
 990
 991
 992
 993
 994
 995
 996
 997
 998
 999
 1000
 1001
 1002
 1003
 1004
 1005
 1006
 1007
 1008




Figure 5

1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041






Figure 6

1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074



Figure

1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107



Suppl. Figure